The company’s valuation had dropped from $6 billion in 2021, to under $150 million after going public and when CEO Anne Wojcicki pushed for a plan to buy it and take it private, the board rejected her ...
A spokesperson for 23andMe would not comment to NPR on what will happen to genetic data, except to express the company’s ...
Financial and security chaos at the once-pioneering genetic testing firm has intensified concerns about user data. Here's how ...